Live Feeds
● LIVE Updated 1d ago · 28 sources tracked

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

AbbVie has reached a deal to acquire Apogee Therapeutics in a transaction valued at $10.9 billion. The acquisition aims to expand AbbVie's immunology portfolio with long-acting drug candidates for inflammatory and immunological conditions. The deal includes prospects for treating eczema.

RSS Source map (25)

What changed

AbbVie announced a $10.9 billion acquisition of Apogee Therapeutics to gain long-acting immunology assets.

Live updates

  1. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

    AbbVie has reached a deal to acquire Apogee Therapeutics in a transaction valued at $10.9 billion. The acquisition aims to expand AbbVie's immunology portfolio with long-acting drug candidates for inflammatory and immunological conditions. The deal includes prospects for treating eczema.

    What's confirmed:

    • AbbVie is acquiring Apogee Therapeutics for $10.9 billion.
    • The acquisition focuses on long-acting immunology and inflammatory drug candidates.
    • The deal includes assets intended for patients with respiratory, dermatologic, and other related inflammatory conditions.
    • The acquisition includes a prospect for treating eczema.
    • The announcement was made on June 22, 2026.

    Still unconfirmed:

    • JPMorgan describes the acquisition as a solid fit.
    • Ademi LLP is investigating if Apogee Therapeutics public shareholders are receiving a fair price.
    confidence 100%